serum eGFR

Overview

Serum eGFR refers to the estimated glomerular filtration rate measured from serum creatinine or related serum biomarkers, and it is one of the most widely used clinical indicators of kidney function. Although not a protein itself, eGFR is a derived renal function metric used in nephrology, transplant medicine, oncology supportive care, and drug development to assess filtration capacity, stage chronic kidney disease (CKD), and monitor changes in renal function over time.

Clinically, serum eGFR is central to evaluating kidney injury, disease progression, and treatment effects. It is commonly interpreted alongside urine albumin-creatinine ratio (UACR) and other markers such as plasma sTIM-3 in longitudinal studies. In recent biomedical research, serum eGFR has been used both as an outcome measure and as a target for interventions intended to slow renal decline, including therapies in IgA nephropathy and studies of kidney function trajectories after acute kidney injury.

Focus of Latest Publications

I notice that only 2 of the 14 publications you provided actually address serum eGFR (estimated glomerular filtration rate as a kidney function metric). The remaining papers discuss EGFR, the epidermal growth factor receptor protein, which is a different entity. Based on a strict reading of the provided abstracts, I can only write a brief section from the two relevant studies:

Recent research has focused on predicting long-term kidney function decline trajectories in high-risk populations using both computational and genetic approaches. A machine learning study developed models to predict membership in high-risk longitudinal EGFR trajectories following acute kidney injury hospitalization, with the goal of identifying patients at risk of rapid progression toward kidney replacement therapy initiation. Separately, a large-scale European investigation examined the shared genetic architecture underlying both EGFR (estimated glomerular filtration rate) and albuminuria, two key chronic kidney disease indicators recognized by Kidney Disease: Improving Global Outcomes guidelines. While previous work has identified independent genetic loci associated with each trait individually, this study sought to elucidate common genetic markers of kidney function that operate both broadly across populations and specifically within type 2 diabetes patients, recognizing that chronic kidney disease represents a substantial global health and economic burden particularly among diabetic individuals.

Note: This section is necessarily brief because only 2 of your 14 provided abstracts actually concern serum eGFR; the other 12 focus on EGFR (epidermal growth factor receptor) in cancer research. If you intended to provide different publications for the EGFR wiki article, please share those abstracts and I can write a fuller synthesis.

Key Publications

• NEWJul MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib-Resistant MET-Amplified, EGFR-Mutated Non-Small Cell Lung Cancer. (Thoracic cancer, 2026, PMID 42381268): "MET amplification is a common resistance mechanism to EGFR-TKIs; however, its effects on receptor dimerization and the resulting dependence on EGFR or MET signaling have not been fully elucidated."
• Jun Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. (Drug development research, 2026, PMID 42207930): "A possible method for improving anti-cancer efficacy is the combination of the inhibition of epidermal growth factor receptor (EGFR) and poly (ADP-ribose) polymerase-1 (PARP-1)."
• Jun Lead Discovery via Scaffold Refinement: Structure-Guided Optimization of 1,2,4-Triazolo[1,5-a]Pyrimidines as Potent Dual EGFR/CDK-2 Inhibitors Targeting Colorectal Carcinoma. (Drug development research, 2026, PMID 42200498): "A unique series of 1,2,4-triazolo[1,5-a]pyrimidine derivatives was designed and synthesized as potential dual inhibitors of EGFR and CDK-2 to circumvent drug resistance in colorectal cancer patients through multi-targeted therapy."
• May Elucidating the molecular mechanisms linking bisphenol A to breast cancer: an integrated study of bioinformatics, machine learning, and molecular docking. (Naunyn-Schmiedeberg's archives of pharmacology, 2026, PMID 42201343): "Five core genes (EGFR, PPARG, MMP12, ADRB2, and KIF11) were identified, all of which demonstrated high diagnostic accuracy (AUC>0.7) in validation sets."
• May Machine learning-based prediction of a high-risk kidney function trajectory class after acute kidney injury. (BMJ health & care informatics, 2026, PMID 42203305): "to predict membership in a high-risk longitudinal estimated glomerular filtration rate (eGFR) trajectory associated with subsequent kidney replacement therapy (KRT) initiation."
• Jun The Association Between Longitudinal Changes in TRACP-5b and Bone Metastasis Progression During Osimertinib Therapy. (Anticancer research, 2026, PMID 42203350): "...in a relatively homogeneous population of patients with epidermal growth factor receptor (EGFR)-mutated NSCLC treated with osimertinib."
• May Mapping shared genetic determinants of eGFR and albuminuria with a focus on type 2 diabetes: a large-scale European study. (BMJ open diabetes research & care, 2026, PMID 42191235): "According to Kidney Disease: Improving Global Outcomes guidelines, key CKD indicators include urine albumin-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR)."
• Jun Identification of Key Genes and Clinical Feature Analyses of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma. (Genetic testing and molecular biomarkers, 2026, PMID 42163810): "Epidermal growth factor receptor (EGFR) mutations are commonly observed in LUAD."
• Jun Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer. (CPT: pharmacometrics & systems pharmacology, 2026, PMID 42166539): "Amivantamab, a bispecific antibody targeting epidermal growth factor and mesenchymal-epithelial transition receptors, was initially approved under accelerated approval as a monotherapy for second-line treatment of non-small cell lung cancer (NSCLC) with exon 20 insertion mutations."
• Jun Extracellular vesicles targeting EGFR inhibit MAOA expression and activity by delivering curcumin for the treatment of asthma. (Nanomedicine (London, England), 2026, PMID 42153286): "To investigate whether curcumin (CUR) delivered by EGFR-targeted extracellular vesicles (EVs) alleviates asthma and to explore the underlying mechanism."